FDA rolls back 'red tape' in move aligned with Trump push to speed up new cures

FDA Commissioner Marty Makary announced the agency will no longer bar submission of de‑identified real‑world evidence (RWE) — a constraint that had limited RWE’s use to just 12 drug approvals in the past 14 years — and is immediately eliminating the requirement for identifiable patient consent in medical device applications while intending to update guidance for drugs and biologics. The change, paired with a shift from a default two‑trial standard to one well‑controlled, statistically powered trial for many approvals, is designed to shorten development timelines, lower R&D costs and broaden the evidentiary base using sources such as SEER, claims databases and EHR networks. For investors, the policy could accelerate time‑to‑market and reduce development spend for biopharma and med‑tech firms—potentially compressing pricing power and prompting valuation re‑assessments—although regulators will still evaluate data quality and most drugs will continue to require clinical trials.

Analysis

FDA Commissioner Marty Makary announced the agency will allow submission of de-identified real‑world evidence (RWE) from sources such as SEER, insurance claims, hospital records and electronic health record networks, removing a prior barrier that limited RWE use to just 12 drug approvals over the past 14 years. The agency is immediately eliminating the identifiable‑patient requirement for medical device applications and intends to update guidance for drugs and biologics, while shifting the default drug standard from two trials to one well‑controlled, statistically powered trial for many approvals.

The policy change is intended to shorten development timelines and reduce R&D costs by broadening acceptable evidence beyond traditional clinical trials, which could accelerate time‑to‑market for some therapies and lower development spending. That outcome could pressure drug price inflation and prompt valuation reassessments across biopharma and med‑tech, but the FDA retains review authority and will reject poor‑quality RWE submissions, so regulatory execution and data quality remain gating factors.

Key risks include persistent requirements for clinical trials in most cases, potential legal or privacy scrutiny around de‑identified datasets, and uneven competitive benefit—firms with established data access and analytic capabilities stand to gain more than those without them.

Key Decisions for Investors

• Reassess valuations and consider modestly overweighting biopharma and med‑tech names that already control or partner for large EHR, claims or registry datasets (e.g., hospital systems, SEER access),
• Monitor FDA guidance updates for drugs and biologics and watch for company filings that cite RWE as a catalyst before materially re‑pricing time‑to‑market or R&D savings in models,
• Prioritize companies with demonstrable data governance and analytic capabilities since the FDA can still reject low‑quality RWE; avoid broad sector bets that assume universal approval acceleration,
• Manage downside risk from potential pricing compression or privacy/legal headwinds via position sizing, hedges or reducing exposure to firms lacking differentiated RWE assets